The multidrug resistant phenotype in clinical practice; evaluation of cross resistance to ifosfamide and mesna after VP16–213, doxorubicin and vincristine (VPAV) for small cell lung cancer
- 1 February 1988
- journal article
- research article
- Published by Elsevier in European Journal of Cancer and Clinical Oncology
- Vol. 24 (2) , 123-129
- https://doi.org/10.1016/0277-5379(88)90242-8
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Three months' treatment with cyclophosphamide, VP-16-213 followed by methotrexate and thoracic radiotherapy for small cell lung cancerCancer, 1985
- Patients with Small-Cell Lung Cancer Treated with Combination Chemotherapy with or without IrradiationAnnals of Internal Medicine, 1985
- Three months treatment with chemotherapy and radiotherapy for small cell lung cancerBritish Journal of Cancer, 1985
- Long-term survivors of small cell carcinoma of the lungThe American Journal of Medicine, 1985
- Potentiation of antitumor agents by calcium channel blockers with special reference to cross-resistance patternsCancer Chemotherapy and Pharmacology, 1985
- Chemotherapy for small cell lung cancer.BMJ, 1985
- A randomised trial of cyclophosphamide pretreatment (‘priming’) before short-duration chemotherapy for small cell lung carcinomaEuropean Journal of Cancer and Clinical Oncology, 1985
- Combined modality treatment of short duration in small cell lung cancerEuropean Journal of Cancer and Clinical Oncology, 1984
- Treatment of ifosfamide-induced urothelial toxicity by oral administration of sodium 2-mercaptoethane sulphonate (MESNA) to patients with inoperable lung cancerEuropean Journal of Cancer and Clinical Oncology, 1983
- PREVENTION OF ISOPHOSPHAMIDE-INDUCED UROTHELIAL TOXICITY WITH 2-MERCAPTOETHANE SULPHONATE SODIUM (MESNUM) IN PATIENTS WITH ADVANCED CARCINOMAThe Lancet, 1980